CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 59 enrolled
Drug / intervention
Brentuximab vedotin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02979522
NCT02979522Phase 2Active
CompareCT.gov

An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Takeda·interventional·Posted Dec 1, 2016·Updated Nov 10, 2025

In Brief

A Phase 2 clinical trial evaluating Brentuximab vedotin, Doxorubicin, and 2 other interventions for Hodgkin Disease. Active but no longer recruiting, targeting 59 participants across 14 sites in 4 countries.

Detailed Summary

The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen, doxorubicin (Adriamycin), vinblastine, and dacarbazine, in pediatric participants with advanced stage newly diagnosed classical CD30+ Hodgkin Lymphoma (HL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Disease
CountriesBrazil, Italy, Japan, United States
Collaborators--

Timeline

Phase 2Active
20172018201920202021202220232024202520262027202820292030
First PostedDec 1, 2016
Enrollment StartSep 6, 2017
Primary CompletionMay 5, 2020
Study CompletionSep 24, 2029
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 9.6 years ago

Interventions

Brentuximab vedotindrug

Brentuximab vedotin infusion

Doxorubicindrug

Doxorubicin infusion

Vinblastinedrug

Vinblastine infusion

Dacarbazinedrug

Dacarbazine infusion